Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- Clinacort (triamcinolone)
- colesevelam
Interactions between your drugs
triamcinolone colesevelam
Applies to: Clinacort (triamcinolone), colesevelam
ADJUST DOSING INTERVAL: Concurrent administration of bile acid sequestrants may delay and/or decrease the absorption of oral corticosteroids. Bile acid sequestrants can bind certain drugs in the intestine to form an insoluble complex that is excreted in the feces. Reduced bioavailability of hydrocortisone has been reported during concomitant administration with cholestyramine and colestipol. It is not known whether the interaction occurs with other bile acid binding resins such as colesevelam or with corticosteroids other than hydrocortisone, but the possibility should be considered.
MANAGEMENT: Oral corticosteroids should be administered at least 1 hour before or 4 to 6 hours after a cholestyramine or colestipol dose, and at least 4 hours before a colesevelam dose.
References (5)
- Johansson C, Adamsson U, Stierner U, Lindsten T (1978) "Interaction by cholestyramine on the uptake of hydrocortisone in the gastrointestinal tract." Acta Med Scand, 204, p. 509-12
- (2002) "Product Information. Questran (cholestyramine)." Par Pharmaceutical Inc
- "Product Information. Colestid (colestipol)." Pharmacia and Upjohn
- Nekl KE, Aron DC (1993) "Hydrocortisone-colestipol interaction." Ann Pharmacother, 27, p. 980-1
- (2001) "Product Information. Welchol (colesevelam)." Daiichi Sankyo, Inc.
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Benlysta
Benlysta infusion is used to treat active systemic lupus erythematosus (SLE) and active lupus ...
Nplate
Nplate is used to prevent bleeding episodes in people with chronic immune thrombocytopenic purpura ...
Cosentyx
Cosentyx (secukinumab) is used to treat plaque psoriasis, psoriatic arthritis, ankylosing ...
Otezla
Otezla (apremilast) is used to treat plaque psoriasis, psoriatic arthritis, and oral ulcers ...
Saphnelo
Saphnelo is used for moderate to severe SLE (lupus) for adults who are also receiving other lupus ...
Skyrizi
Skyrizi (risankizumab) is used to treat plaque psoriasis, psoriatic arthritis, ulcerative colitis ...
Stelara
Stelara (ustekinumab) is used to treat Crohn's disease, ulcerative colitis, plaque psoriasis, and ...
Humira
Humira is a tumor necrosis factor blocker used to treat many inflammatory conditions in adults ...
Ilumya
Ilumya (tildrakizumab) is used to treat moderate-to-severe plaque psoriasis to reduce plaques ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.